| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | |
|---|---|---|---|---|---|---|
Cash Flows From Operating Activities: | ||||||
Net loss | ||||||
-224,338 | -198,607 | -117,500 | -95,708 | -62,124 | -39,444 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
165 | 233 | 163 | 120 | 56 | 2 | |
Amortization of deferred debt costs and debt discount | ||||||
1,342 | 6,921 | 4,566 | 411 | - | - | |
Value of common stock issued for patent license | ||||||
0 | 0 | 67 | 0 | - | - | |
Accretion of back-end facility fee | ||||||
0 | 0 | 109 | -130 | -59 | 86 | |
Accretion of back-end facility fee | ||||||
106 | 0 | 0 | - | - | - | |
Loss on disposal of property and equipment | ||||||
-46 | 0 | 0 | - | - | -2 | |
Stock-based compensation expense | ||||||
22,715 | 12,575 | 9,724 | 4,722 | 4,614 | 2,515 | |
Interest expense Payment-in-kind (PIK) | ||||||
3,212 | 0 | 0 | - | - | - | |
Change in fair value of derivative financial instrumentswarrants | ||||||
4,340 | 106 | -394 | 1,362 | 149 | -1,933 | |
Common stock issued for interest on Notes | ||||||
0 | 2,445 | 0 | 0 | - | - | |
Debt conversion expense | ||||||
1,209 | 40,158 | 0 | 0 | - | - | |
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
6,491 | 0 | 0 | - | - | - | |
Inventories | ||||||
11,574 | 5,640 | 0 | 0 | - | - | |
Security deposits | ||||||
31 | 0 | -180 | -69 | - | -5 | |
Accounts payable and accrued expenses | ||||||
8,669 | 11,546 | 1,867 | 316 | 7,084 | 4,442 | |
Prepaid expenses and other current assets | ||||||
3,580 | -2,416 | -531 | 124 | 2,171 | 484 | |
Accrued interest expense on senior convertible notes | ||||||
-61 | -1,694 | -512 | 2,500 | - | - | |
Total Adjustments | ||||||
11,449 | 68,854 | 16,511 | 6,644 | 9,493 | 8,319 | |
Net Cash used in Operating Activities | ||||||
-212,889 | -129,753 | -100,989 | -89,064 | - | -31,125 | |
Net Cash used in Operating Activities | ||||||
- | - | - | - | -52,631 | - | |
Cash Flows From Investing Activities: | ||||||
Loans to related parties | ||||||
- | - | - | - | 270 | 1,764 | |
Net sales (purchases) of available-for-sale securities | ||||||
0 | -50,097 | 200 | 0 | 30,000 | - | |
Net purchases of available-for-sale securities | ||||||
- | - | - | - | - | 20,000 | |
Additions to property and equipment | ||||||
210 | 297 | 50 | 173 | 615 | 28 | |
Repayment on ContraVir loan receivable | ||||||
- | - | - | 455 | - | - | |
Net Cash used in Investing Activities | ||||||
-210 | 49,800 | -250 | 282 | - | -21,792 | |
Net Cash provided by (used in) Investing Activities | ||||||
- | - | - | - | -30,885 | - | |
Cash Flows From Financing Activities: | ||||||
Proceeds of sale of common stock, net of issuance costs | ||||||
173,802 | 89,845 | 14,268 | 30,700 | 94,734 | 55,862 | |
Proceeds of sale of common stock ContraVir | ||||||
- | - | - | 3,224 | - | - | |
Issuance of Senior Convertible Debentures | ||||||
- | - | - | 200,000 | - | - | |
Fees and expenses note conversions | ||||||
0 | 711 | 0 | 0 | - | - | |
Payment for deferred financing costs | ||||||
1,591 | 0 | 0 | 12,747 | - | - | |
Proceeds from borrowings, net of issuance costs | ||||||
95,140 | 0 | 0 | - | - | - | |
Fees and expenses sale of common stock | ||||||
- | - | - | 861 | 5,623 | 3,774 | |
Proceeds from exercise of warrants | ||||||
0 | 11,331 | 1,012 | 0 | - | - | |
Proceeds from exercise of stock options | ||||||
347 | 222 | 1,142 | 36 | 119 | - | |
Distribution associated with ContraVir Spinoff | ||||||
- | - | - | 3,230 | - | - | |
Net Cash (used in) provided by Financing Activities | ||||||
267,698 | 100,687 | 16,422 | 217,122 | - | 52,088 | |
Net increase (decrease) in cash and cash equivalents | ||||||
54,599 | 20,734 | -84,817 | 128,340 | - | -829 | |
Net Cash provided by Financing Activities | ||||||
- | - | - | - | 89,230 | - | |
Net decrease in cash and cash equivalents | ||||||
- | - | - | - | 5,714 | - | |
Supplementary disclosure of cash flow information: | ||||||
Cash paid for interest on long term debt | ||||||
1,396 | 5,939 | 13,379 | 0 | - | - | |
Cash paid for taxes | ||||||
20 | 45 | 258 | 55 | 81 | 50 | |
Supplementary disclosure of non-cash investing and financing activities: | ||||||
Distribution of net assets of ContraVir | ||||||
- | - | - | 84 | - | - | |
Conversion of senior convertible notes to Synergy Common Stock | ||||||
4,912 | 137,941 | 40,989 | 0 | - | - | |
Amount added to principal of term loan for Payment-in-kind (PIK) interest | ||||||
3,212 | 0 | 0 | - | - | - | |
Non-cash tenant improvement allowance | ||||||
587 | 0 | 0 | - | - | - | |
Fair value of warrants classified to derivative liability | ||||||
21,706 | 0 | 0 | - | - | - | |